Wave Life Sciences (WVE) Cash & Equivalents (2014 - 2026)

Wave Life Sciences (WVE) has 13 years of Cash & Equivalents data on file, last reported at $368.0 million in Q2 2026.

• Quarterly Cash & Equivalents rose 76.5% year-over-year to $368.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $368.0 million (up 76.5% YoY) and the FY2025 annual result came in at $602.1 million, up 99.31% from the prior year.
• Cash & Equivalents retreated to $368.0 million in Q2 2026, from $544.6 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $602.1 million in Q4 2025 to a low of $88.5 million in Q4 2022.
• A 5-year average of $239.0 million and a median of $198.3 million in 2023 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents plunged 41.22% — and 2023, when it soared 126.39%.
• Tracing WVE's Cash & Equivalents over 5 years: stood at $88.5 million in 2022, then surged by 126.39% to $200.4 million in 2023, then soared by 50.77% to $302.1 million in 2024, then jumped by 99.31% to $602.1 million in 2025, then sank by 38.88% to $368.0 million in 2026.
• The last three Cash & Equivalents figures came in at $368.0 million (Q2 2026), $544.6 million (Q1 2026), and $602.1 million (Q4 2025), per Business Quant data.